“The Delaware court's scathing comments about the stock issued to management should put an end, once and for all, to those who claim Pourhassan sold about $15 million in such stock for the benefit of the company.”
His claim in 2020 that he sold the shares to benefit the company is the one of the most ridiculous statements he’s ever made. He’d been better off simply saying, “This is a good time to take profits from a recent low of .30 cents.”
“Once competent management is in place, we can finally get leronlimab approved for HIV, and hopefully other indications, and be speared the constant drumbeat of false touts.”
Agreed. The time for the annual shareholders meeting is quickly approaching and I suspect this years meeting will be very interesting.
News 
Market Data 
Discover 
AI
